Semaglutide News and Research

Latest Semaglutide News and Research

SGLT-2 inhibitors do not increase the risk of UTIs in diabetics, concludes study

A new study has shown that SGLT-2 inhibitors used in the treatment of type 2 diabetes do not increase the risk of UTIs over other anti-diabetic medications.

31 Jul 2019

FDA approves first non-insulin drug for treatment of pediatric patients with type 2 diabetes

The U.S. Food and Drug Administration today approved Victoza (liraglutide) injection for treatment of pediatric patients 10 years or older with type 2 diabetes.

18 Jun 2019

Diabetes drug reduces cardiovascular events and kidney problems, study finds

A clinical trial that followed more than 9,900 people in 24 countries has found that the drug dulaglutide reduced cardiovascular events and kidney problems in middle-aged and older people with Type 2 diabetes.

10 Jun 2019

No lasting improvement in insulin secretion with diabetic medication

Adults with type 2 diabetes mellitus respond to medical treatment by producing more insulin, but there is no long-term effect on insulin secretion after treatment stops, concluded a pair of clinical trials.

9 Jun 2019

Diabetes drug could help with smoking cessation

Phillip Robinson has gone from 10 cigarettes a day to one or two every other day after enrolling in a smoking cessation clinical trial launched by researchers at The University of Texas Health Science Center at Houston

30 Apr 2019

Study results of a potential drug to treat Type 2 diabetes in children announced

Results of a recently completed clinical trial of a potential drug to treat Type 2 diabetes in children were announced Sunday [April 28] at the Pediatric Academic Societies 2019 meeting in Baltimore, Md. The New England Journal of Medicine also published the findings.

29 Apr 2019

Study provides framework for developing Ebola virus therapeutic under FDA Animal Rule

The U.S. Army Medical Research Institute of Infectious Diseases today announced that, for the first time, the U.S. Food and Drug Administration has provided formal regulatory agreement for use of an animal model to support development of a drug candidate, remdesivir, for treating deadly Ebola virus infections.

29 Mar 2019

New Metrohm Eco Titrator makes titration simple, safe, and reliable

When something goes wrong in quality control, the reputation of the brand concerned is at stake. Better to exclude risks in the first place.

From Metrohm USA Inc. 15 Mar 2019

Bariatric surgery changes the way our body senses food

How bariatric surgery helps people with obesity and diabetes is related to changes in the way the gut senses food and nutrients after the operation, researchers report February 5 in the journal Cell Reports.

8 Feb 2019

The T2B Infrastructure Center for Respiratory Disease set to enter into the final phase

The Korea Institute of Toxicology (KIT·Chief Dr. Song, Chang-woo) National Center for Efficacy Evaluation of Respiratory Disease Product (NCER·Chief Dr. Lee, Kyu-hong) obtained on January 10 the final decision from the Ministry of Health and Welfare that the T2B Infrastructure Center for Respiratory Disease would enter into the final phase (second phase) with funding of 3 billion KRW over two years.

4 Feb 2019

Gut immune cells could be responsible for metabolism changes finds study

A new study has shown that the immune cells within the gut could be related to the rate of metabolism. The results of the new study titled, “Gut intraepithelial T cells calibrate metabolism and accelerate cardiovascular disease,” are published in the latest issue of the journal Nature.

31 Jan 2019

New bacterial species may help fight obesity and metabolic disorders

The MyNewGut project has discovered new bacterial species and strains in healthy people that seem to be effective against obesity, metabolic and mental disorders related to stress and obesity (e.g. depression).

17 Dec 2018

Liraglutide drug associated with lower risk of cardiovascular events

Real world data from a large Nordic study shows that use of liraglutide, a drug for type 2 diabetes, is associated with a lower risk of myocardial infarction, stroke or cardiovascular death.

6 Dec 2018

New diabetes drugs linked to increased risk of lower-limb amputation and ketoacidosis

The use of a new class of drugs in the treatment of type 2 diabetes, so called SGLT2 inhibitors, are linked to a twofold increased risk for lower-limb amputation as well as diabetic ketoacidosis, a serious diabetes complication.

14 Nov 2018

Emergex completes toxicology testing on gold nanoparticle carrier system for vaccine platform

Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces the successful completion of preclinical toxicology testing on the gold nanoparticle carrier system that forms the fundamental basis for Emergex's entire infectious disease vaccine platform.

24 Oct 2018

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

HealthCore, Inc., the outcomes research subsidiary of Anthem, Inc. and Novo Nordisk Inc., which manufacturers the once weekly GLP-1 receptor agonist Ozempic (semaglutide), are working together to launch the first of its kind pragmatic study to understand the benefits of semaglutide as compared with all other available diabetes drugs in a real-world pragmatic clinical trial for Type 2 diabetes - one of the nation's fastest growing chronic diseases.

17 Oct 2018

Study investigates effects of glucose-lowering drug in preventing damage to the kidneys

New research presented at the annual meeting of the European Association for the Study of Diabetes and published simultaneously in The Lancet Diabetes & Endocrinology shows how the glucose-lowering drug lixisenatide can slow or prevent damage to the kidneys in macro-albuminuric patients with type 2 diabetes mellitus and cardiovascular disease.

3 Oct 2018

Semaglutide News and Research

Latest Semaglutide News and Research

SGLT-2 inhibitors do not increase the risk of UTIs in diabetics, concludes study

FDA approves first non-insulin drug for treatment of pediatric patients with type 2 diabetes

Diabetes drug reduces cardiovascular events and kidney problems, study finds

No lasting improvement in insulin secretion with diabetic medication

Diabetes drug could help with smoking cessation

Study results of a potential drug to treat Type 2 diabetes in children announced

Study provides framework for developing Ebola virus therapeutic under FDA Animal Rule

New Metrohm Eco Titrator makes titration simple, safe, and reliable

Bariatric surgery changes the way our body senses food

The T2B Infrastructure Center for Respiratory Disease set to enter into the final phase

Gut immune cells could be responsible for metabolism changes finds study

New bacterial species may help fight obesity and metabolic disorders

Liraglutide drug associated with lower risk of cardiovascular events

New diabetes drugs linked to increased risk of lower-limb amputation and ketoacidosis

Emergex completes toxicology testing on gold nanoparticle carrier system for vaccine platform

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

Study investigates effects of glucose-lowering drug in preventing damage to the kidneys

Genetic score helps predict future major coronary events, shows study

INTEGRA’s electronic pipettes simplify work in GLP environments

Study shows new options to lower heart disease risk in people with diabetes

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Semaglutide News and Research

Latest Semaglutide News and Research

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Newsletters you may be interested in